



an Open Access Journal by MDPI

## Recent Advances in Arthritis and Tendinopathy

Guest Editors:

### Dr. Po-Ting Wu

Department of Orthopaedics,  
National Cheng Kung University  
Hospital, College of Medicine,  
National Cheng Kung University,  
Tainan 70428, Taiwan

### Dr. Chung-Hwan Chen

Graduate Institute of Medicine,  
College of Medicine, Kaohsiung  
Medical University, Kaohsiung  
80701, Taiwan

### Dr. Tulyapruerk Tawonsawatruk

Department of Orthopaedics,  
Faculty of Medicine, Ramathibodi  
Hospital, Mahidol University,  
Bangkok 10400, Thailand

### Message from the Guest Editors

Arthritis and tendinopathy are two of the most common musculoskeletal disorders. However, current clinical treatment strategies cannot yield satisfactory results. Recently, an increasing number of biomarkers, microRNAs, lncRNAs, and cellular responses have been proposed to be involved in pathogenesis and would be therapeutic candidates in addition to stem cells, exosomes, biomaterials, and nanomaterials. Reducing inflammation, apoptosis, or senescence, enhancing M2 macrophage polarization, and maintaining extracellular matrix homeostasis in cartilage or tendons are common therapeutic approaches. Therefore, the Special Issue aims to highlight “diagnosis” and “treatment” of arthritis and tendinopathy. Articles presenting new strategies supported by experimental or clinical results and comprehensive evidence-based reviews are welcome. This issue will provide new insight into pathogenesis and treatment of arthritis and tendinopathy.

Deadline for manuscript  
submissions:

**closed (31 May 2024)**



[mdpi.com/si/155865](https://mdpi.com/si/155865)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)